To recover your password please fill in your email address
Please fill in below form to create an account with us
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostrate cancer (ANZUP1303).
See ANZCTR for full trial details >
|
Trial Summary: |
To determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy with a lutenising hormone releasing hormone analogue (LHRHA) in men having radiotherapy for localised prostate cancer at high risk of recurrence. |
|
Supported By: |
Astellas Scientific and Medical Affairs Inc. |
|
Eligibility: |
Men (≥ 18 years) with localised prostate cancer at high risk for recurrence deemed suitable for external beam radiation therapy. |
|
Registration ID: |
ACTRN12614000126617 |
|
Participation: |
International |
|
Australian Lead Group: |
ANZUP |
|
Status: |
Follow-up |
|
Activation Date: |
28/03/2014 |
|
Chairs: |
Prof Scott Williams and Dr Paul Nguyen |
|
Contact: |